1992). Cytogenetic abnormalities have been reported in a few cases of HBL, among them trisomy of chromosomes 20, 2, and 8, and of the long arm of chromosome 1 (Mascarello and Krous 1992; Tonk et al. 1994; Fletcher et al. 1991; Bardi et al. 1992; Simon et al. 1991; Dressler et al. 1993) , although these features are not observed in a majority of karyotyped HBL tumors. However, loss of heterozygosity (LOH) around 11p15.5 is a frequent observation in HBLs (Simms et al. 1995) , and abnormalities in that region are associated with Beckwith-Wiedeman syndrome (BWS). Recently, Hatada et al. (1996) showed that the p57
Kip2 gene is imprinted in BWS; alteration of this gene might be involved in the development of HBLs as well. Other investigators have described a mutation of the CTNNB1 gene in HBLs that results in intense cytoplasmic staining of beta-catenin and accumulation of this protein in the nuclei of tumor cells, but that observation has not been confirmed by other laboratories (Blaker et al. 1999 ). In our own recent deletionmapping study, we defined an interstitial deletion at 4q21-22 in the germline of an HBL patient within an interval of 8 cM between D4S2964 and D4S2966, which overlaps with the commonly deleted region previously described in adult hepatocellular carcinomas (HCCs; Terada et al. 2001) . Those findings suggest that certain genetic events may occur in both types of hepatic malignancy.
We and others previously cloned the SOCS1 gene (suppressor of cytokine signaling 1, also termed JAB1 and SSI-1), encoding a JAK-binding protein that regulates the signal-transduction pathway of JAK/STAT (Janus kinase signal transducers and activators of transcription). SOCS1 protein relays signals into cells from various cytokines in the extracellular matrix (Naka et al. 1997; Starr et al. 1997; Endo et al. 1997) . We and others have described inactivation by methylation of the SOCS1 gene in HCCs Yoshikawa et al. 2001) .
In the present study, we investigated 15 human HBL tumors for SOCS1 abnormalities, and identified in a substantial portion of HBL tumor tissues a marked reduction of SOCS1 expression and associated hypermethylation of the gene's GC-rich region. The results suggest that dysregulation of the JAK/STAT signal transduction path-Introduction Hepatoblastoma (HBL) is an embryonic tumor observed predominantly in children. However, the molecular mechanisms underlying transformation of liver cells in this condition remain obscure (for review, see Mascarello and Krous way plays a role in the development of this embryonic liver tumor.
Materials and methods
Tumor specimens and DNA extraction Tumor samples and corresponding noncancerous tissues were obtained from 15 patients with HBL who underwent surgery at Saitama Cancer Center Hospital. The study was approved by the Institutional Review Board, and informed consent was obtained from the families of all participants prior to surgery. Clinical and pathology data are listed Table 1 . Portions of these tissues were frozen immediately after surgery and stored at Ϫ80°C. DNAs were extracted later according to standard procedures.
Immunohistochemistry of SOCS1 protein in HBL tumors
Immunohistochemical staining was performed with mouse anti-SOCS1 polyclonal antibody on formalin-fixed, paraffin-embedded HBL tissues using the streptoavidin biotin peroxidase complex method. After heat treatment, peroxidase activity was suppressed by 3% hydrogen peroxide in methanol for 30 min. Primary antibody was applied to the slides and incubated overnight at 4°C. SOCS1 protein was detected by SAB-Po kit (Nichiren Corporation, Tokyo, Japan). The sections were treated with biotinylated rabbit anti-mouse immunoglobulins (Dako code # E0432) for 1 h. After three washes with phosphate-buffered solution (PBS), samples were incubated with 100 µg/ml streptoavidin (Dako code #K0377A) and biotinylated horseradish peroxidase (Dako code #K0377B) for 10 min, followed by three more washes in PBS. The slides were covered with 0.05% 3-3Ј diaminobenzidine containing 0.01% hydrogen peroxide for 7 min, rinsed with distilled water, dehydrated in ethanol, and overlaid with coverglasses using mounting medium.
Methylation assay by bisulfite-modified polymerase chain reaction (PCR)
One microgram of each DNA sample in a volume of 50 µl was denatured by NaOH (final concentration, 0.2 M) for 10 min at 37°C. For samples containing only nanogram quantities of human DNA, 1 µg of salmon-sperm DNA (Sigma, St. Louis, MO, USA) was added as a carrier before modification. Thirty microliters of 10 mM hydroquinone (Sigma) and 520 µl of 3 M sodium bisulfite (Sigma) at pH 5, both freshly prepared, were added and mixed, and the samples were incubated under mineral oil at 50°C for 16 h. Bisulfite-modified DNAs were purified using the Wizard DNA purification resin according to the manufacturer's instructions (Promega, Madison, WI, USA) and eluted into 50 µl of water. Modification was completed by treatment with NaOH (final concentration, 0.3 M) for 5 min at room temperature, followed by ethanol precipitation. Each DNA sample was resuspended in water and either used immediately or stored at 22°C.
Aliquots of unmodified DNA (50-100 ng) in final volumes of 50 µl included 5% dimethyl sulfoxide. All DNAs were amplified using primers derived from the nucleotide sequence of the SOCS1 gene deposited in the Genome Database (GDB) (accession number U88326). Primers were designed to amplify the GC-rich region within the SOCS1 promoter, as follows: 5Ј-GTTGTAGGATGGGG TCGCGGTCGC-3Ј and 5Ј-CTACTAACCAAACTAAA ATCCGCG-3Ј for detection of methylated alleles, and 5Ј-GTTGTAGGATGGGGTTGTGGTTGT-3Ј and 5Ј-CTAC TAACCAAACTAAAATCCACA-3Ј for detection of unmethylated alleles.
Analysis of the genomic SOCS1 region in HBLs
Genomic DNAs from the 15 HBL tumors were screened for mutations using a single pair of primers for the PCR (5ЈGGAAGAGCTCCGCGGAGTACAGAGCCCATT-3Ј and 5Ј-AACCCAGGCCGGGGAGGGTACCCACAG GT-3Ј) that were designed to amplify the entire coding region of the SOCS1 gene. The PCR products were sequenced directly using primers designed to sequence overlapping segments. Nucleotides were determined by the BigDye method terminator cycle-sequencing method (Applied Biosystems, Foster City, CA, USA) using an autosequencer (ABI PRISM 377; Applied Biosystems).
To examine allelic losses at 16p13.13, we used the chromosomal location of the SOCS1 gene, primers GT356F (5Ј-TAGGTACAGTGACCTAAAGC-3Ј) and GT356R (5Ј-CTGCTGAATCATGAAGCTGA-3Ј), to amplify the dinucleotide-repeat sequence present on a genomic cosmid clone, super-cos 356d7 (GDB #AC002286), which contains both the CA-repeat and the entire SOCS1 gene (Naka et al. 1997) .
Results
Reduced staining of SOCS1 in HBL tumors Bisulfite-modified amplification of the SOCS1 promoter region
Previously we and others had demonstrated hypermethylation and combined loss of the remaining allele as the predominant mechanisms for silencing the SOCS1 gene in human HCCs (Naka et al. 1997; Starr et al. 1997) . To investigate the methylation status of the SOCS1 promoter region in HBLs, we performed PCR experiments based on bisulfite modification of DNA from all 15 HBL tumor specimens. Figure 2 displays representative results, which demonstrate that, in multiple cases, HBL tumor-derived DNA revealed no unmethylated allele(s). We observed hypermethylation of SOCS1 alleles in 7 of the 15 HBLs examined (tumors T1, T2, T7, T8, T9, T10, and T11; summarized in Table 1 ). Six of the hypermethylated tumors had shown marked reduction of SOCS1 expression, as revealed by immunohistochemistry (Table 1) .
Hypermethylation as a mechanism for inactivating SOCS1
We investigated the possibility of other genetic mechanisms to account for inactivation of the SOCS1 gene in the HBL tumors, specifically allelic loss at 16p13.13 and somatic mutation within the SOCS1 gene. Analysis of LOH using a microsatellite DNA marker (GTcos356) that lies approximately 3 kb downstream of the translation-initiation site of SOCS1 within the genomic cosmid clone 356d7, demonstrated retention of heterozygosity at this locus for all 13 HBL tumors that were informative for the marker. Moreover, direct sequencing of the entire coding region revealed no somatic mutations in the SOCS1 gene in any of the 15 HBL tumors. These results, taken together with the results of our methylation analysis, suggest that hypermethylation of the promoter region is the predominant mechanism for inactivation of the SOCS1 gene in HBL tumors.
Discussion
Most embryonic tumors may be defined as immature tissue that continues to proliferate inappropriately because of a disturbance of the growth mechanism at an early stage of differentiation (Koufos et al. 1985) . That notion is supported by evidence showing blocked ontogeny/maturation arrest of stem cells, in which aberrant differentiation and proliferation of stem cells eventually induce malignant transformation. HBL may belong to a class of tumors that arise through genetic alteration at the stem-cell level, although a number of genetic alterations may underlie the genesis of HBL. For example, the association of HBL tumors with an impaired imprinted gene in BWS patients, recently described, suggests that epigenetic mechanisms such as methylation status play roles in HBL development (Sell 1993) .
Hypermethylation is recognized as one of the mechanisms that can inactivate tumor suppressor genes, in this Fig. 1 . Representative photomicrographs illustrating immunohistochemical staining of SOCS1 protein in the cytoplasm of normal hepatocytes and marked reduction in hepatoblastoma (HBL) cells Fig. 2 . Bisulfite-modified polymerase chain reaction (PCR) assay of methylation status of the SOCS1 gene in eight primary HBL tumors and paired nontumorous tissues. For the modification experiments, we used 1-µg aliquots of DNA from HBLs (T) and adjacent nontumorous liver cells (N). PCR amplifications involved methylationspecific primer pairs for detection of methylated alleles (M) and unmethylation-specific primer pairs for unmethylated alleles (U). The majority of the tumor samples shown here were hypermethylated case by repressing their transcription (Jones and Laird 1999 ). An increasing number of examples include hypermethylation of RB1, VHL, MLH1, CDKN2A, CDKN2B, APC, or H-cadherin in various types of cancers (Sato et al. 1998) . We have documented here a reduction in SOCS1 expression in HBLs when this gene or its promoter region is hypermethylated. Hypermethylation of SOCS1 was in fact a frequent event in the HBLs we examined, indicating that this mechanism plays a predominant role in the oncogenesis of hepatic precursor cells. The chromosomal region harboring the SOCS1 gene, 16p13-pter, is a known hotspot of hypermethylation in HCCs as well (Kanai et al. 1996) ; moreover, the region commonly deleted in HCCs in our previous study overlaps the SOCS1 locus. The discrepancy between HCC and HBL as regards allelic loss around the SOCS1 locus underscores the point that different epigenetic mechanisms may operate in the two types of hepatic tumor, especially in relation to the genomic imprinting recently described in this chromosomal region. SOCS1 functions as a negative regulator of the JAK/ STAT signaling pathway (Wen et al. 1995) . Emerging evidence strongly implicates abnormal activation of JAK/ STAT signaling during oncogenic transformation. Constitutive activation of Stat3 proteins is frequent in tumor cells (Wen et al. 1995) , suggesting that aberrant Stat3 signaling plays a part in malignant progression. The STAT proteins are latent transcriptional factors that are activated by phosphorylation of tyrosine residues in response to interaction with cytokine receptors at the cell surface. In regenerating liver, interleukin-6 may induce hepatocyte proliferation by activating STAT3 (Ichiba et al. 1998; Narazaki et al. 1998) . Therefore, dysregulation of this pathway might profoundly alter growth of liver cells (Blaker et al. 1999) . In the present study, we demonstrated that the normal suppression of the JAK/STAT signaling pathway by SOCS1 is impaired in HBL tumors by an epigenetic mechanism. Identification of the precise mechanism(s) controlling differentiation of 
